CIK 0001520262 · Large accelerated filer
Alkermes plc.
Sign in to watch- Ticker
- ALKS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981007018
- Phone
- 00-353-1-772-8000
- Business address
- CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN 4, Ireland, 00000
- Former names
- ANTLER SCIENCE TWO PLC, Antler Science Two Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,070,874
- in 5 filings, $1.1M under 10b5-1 plans
Net −$1,070,874. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-05 | Jackson Blair Curtis EVP, Chief Operating Officer | Grant or award | +28,810 | 230,178 | ||
| 2026-02-05 | Jackson Blair Curtis EVP, Chief Operating Officer | Shares withheld for taxes | −8,626 | $33.55 | $289K | 221,552 |
| 2026-02-05 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Grant or award | +25,352 | 83,092 | ||
| 2026-02-05 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Shares withheld for taxes | −7,454 | $33.55 | $250K | 75,638 |
| 2026-02-05 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Grant or award | +25,352 | 230,726 | ||
| 2026-02-05 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Shares withheld for taxes | −7,619 | $33.55 | $256K | 223,107 |
| 2026-02-02 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 | +5,000 | $19.34 | $97K | 66,740 |
| 2026-02-02 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 | −5,000 | $34.24 | $171K | 61,740 |
| 2026-02-02 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 | −4,000 | $33.54 | $134K | 57,740 |
| 2026-02-02 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −5,000 | 26,356 | ||
| 2026-02-02 | Cooke Shane Director | Option exercise 10b5-1 | +61,200 | $31.64 | $1.9M | 164,944 |
| 2026-02-02 | Cooke Shane Director | Sale 10b5-1 | −29,087 | $34.34 | $999K | 135,857 |
| 2026-02-02 | Cooke Shane Director | Sale 10b5-1 | −32,113 | $34.78 | $1.1M | 103,744 |
| 2026-02-02 | Cooke Shane Director | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −61,200 | 0 | ||
| 2026-01-08 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 | +5,000 | $19.34 | $97K | 66,740 |
| 2026-01-08 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 | −5,000 | $30.00 | $150K | 61,740 |
| 2026-01-08 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −5,000 | 31,356 | ||
| 2026-01-02 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 | −4,000 | $28.00 | $112K | 61,740 |
| 2025-12-03 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 | +3,748 | $19.34 | $72K | 69,488 |
| 2025-12-03 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 | −3,748 | $30.00 | $112K | 65,740 |
Page 10 of 41 · 804 trades